Human Respiratory Syncytial Virus and Hospitalization in Young Children in Italy

Overview

Journal Ital J Pediatr

Publisher Biomed Central

Specialty Pediatrics

Date 2018 May 6

PMID 29728106

Citations 20

Authors

Parvane Kuhdari

Federica Brosio

Cristina Malaventura

Armando Stefanati

Andrea Orsi

Giancarlo Icardi

Giovanni Gabutti

Affiliations

Soon will be listed here.

Abstract

Background: Human respiratory syncytial virus (hRSV) is ubiquitous and causes respiratory diseases in both children and adults. Worldwide, hRSV pneumonia is the second cause of postnatal infant death after malaria. Given the high impact in terms of morbidity, mortality and costs, especially in the pediatric population, hRSV is recognized as a global health problem and the WHO, in view of the availability of new vaccines, has urged an active surveillance program of virus-related infections. The aim of this study has been to evaluate the impact of hRSV infections in the Italian population, particularly the pediatric one, in terms of hospitalizations.

Methods: In the period 2001-2014, Hospital Discharge Records (HDRs) with the following diagnosis codes included in the primary diagnosis were evaluated: 466.11 (hRSV bronchiolitis), 480.1 (hRSV pneumonia) and 796 (hRSV). HDRs were supplied by the National Archive of HDRs data, Ministry of Health.

Results: During the period 2001-2014, 57,656 hospital admissions due to hRSV pathologies were performed. Most hospitalizations (88.8%) involved patients with less than 1 year of age. Considering only primary diagnosis, 93% of the admissions were due to bronchiolitis, 5% to pneumonia and 2% to not otherwise specified hRSV infections. In the period 2001-2014, the hospitalization rate in 0-2 years old children, was equal to 224.8, 9.6 and 4.6/100,000 for hRSV bronchiolitis, hRSV pneumonia and not otherwise specified hRSV infection, respectively.

Conclusions: This study confirms the high impact of hRSV on the pediatric population in the age class 0-4 years, with a peak in the first 12 months of life. Most hospitalizations were urgent, although the duration of the hospital stay was for the most part less than a week, with ordinary discharge at home. Pending the conclusion of ongoing clinical trials on different hRSV vaccine types, it is extremely important to have updated data on the impact of hRSV-related pathologies in the various age groups.

Citing Articles

Calabro G, Rizzo C, Domnich A, de Waure C, Rumi F, Bonanni P J Prev Med Hyg. 2024; 65(2 Suppl 1):E1-E159.

PMID: 39554593 PMC: 11567645. DOI: 10.15167/2421-4248/jpmh2024.65.2s1.

First real-world data on universal respiratory syncytial virus prophylaxis with Nirsevimab in infants.

Orsi A, Scarpaleggia M, Baldo V, Barbone F, Chironna M, Giuffrida S J Prev Med Hyg. 2024; 65(2):E172-E187.

PMID: 39430977 PMC: 11487721. DOI: 10.15167/2421-4248/jpmh2024.65.2.3329.

Trends in hospitalizations of children with respiratory syncytial virus aged less than 1 year in Italy, from 2015 to 2019.

Cutrera R, dAngela D, Orso M, Guadagni L, Vittucci A, Bertoldi I Ital J Pediatr. 2024; 50(1):119.

PMID: 38902751 PMC: 11191168. DOI: 10.1186/s13052-024-01688-9.

RSV Disease Burden in Primary Care in Italy: A Multi-Region Pediatric Study, Winter Season 2022-2023.

Scarpaci M, Bracaloni S, Esposito E, De Angelis L, Baglivo F, Casini B Influenza Other Respir Viruses. 2024; 18(4):e13282.

PMID: 38622776 PMC: 11018906. DOI: 10.1111/irv.13282.

Experience of an Italian Pediatric Third Level Emergency Department during the 2022-2023 Bronchiolitis Epidemic: A Focus on Discharged Patients and Revisits.

Iudica G, Franzone D, Ferretti M, Tubino B, Santaniello S, Brisca G Children (Basel). 2024; 11(3).

PMID: 38539303 PMC: 10968752. DOI: 10.3390/children11030268.

References

Medici M, Arcangeletti M, Rossi G, Lanari M, Merolla R, di Luzio Paparatti U . Four year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the "Osservatorio VRS" Study (2000-2004). New Microbiol. 2006; 29(1):35-43. View

Gil-Prieto R, Gonzalez-Escalada A, Marin-Garcia P, Gallardo-Pino C, Gil-de-Miguel A . Respiratory Syncytial Virus Bronchiolitis in Children up to 5 Years of Age in Spain: Epidemiology and Comorbidities: An Observational Study. Medicine (Baltimore). 2015; 94(21):e831. PMC: 4616425. DOI: 10.1097/MD.0000000000000831. View

. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014; 134(2):e620-38. DOI: 10.1542/peds.2014-1666. View

Pignotti M, Leo M, Pugi A, De Masi S, Biermann K, Galli L . Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease. Pediatr Pulmonol. 2016; 51(10):1088-1096. DOI: 10.1002/ppul.23561. View

Montieri S, Puzelli S, Ciccozzi M, Calzoletti L, Di Martino A, Milia M . Amino acid changes in the attachment G glycoprotein of human respiratory syncytial viruses (subgroup A) isolated in Italy over several epidemics (1997-2006). J Med Virol. 2007; 79(12):1935-42. DOI: 10.1002/jmv.21012. View

Zuccotti G, Dilillo D, Zappa A, Galli E, Amendola A, Martinelli M . Epidemiological and clinical features of respiratory viral infections in hospitalized children during the circulation of influenza virus A(H1N1) 2009. Influenza Other Respir Viruses. 2011; 5(6):e528-34. PMC: 5780670. DOI: 10.1111/j.1750-2659.2011.00264.x. View

Graham B . Vaccines against respiratory syncytial virus: The time has finally come. Vaccine. 2016; 34(30):3535-41. PMC: 4912855. DOI: 10.1016/j.vaccine.2016.04.083. View

. Meeting of the Strategic Advisory Group of Experts on immunization, April 2016 – conclusions and recommendations. Wkly Epidemiol Rec. 2016; 91(21):266-84. View

Pierantoni A, Esposito M, Ammendola V, Napolitano F, Grazioli F, Abbate A . Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates. Mol Ther Methods Clin Dev. 2015; 2:15018. PMC: 4441047. DOI: 10.1038/mtm.2015.18. View

10.

Drysdale S, Sande C, Green C, Pollard A . RSV vaccine use--the missing data. Expert Rev Vaccines. 2015; 15(2):149-52. DOI: 10.1586/14760584.2016.1114419. View

11.

Nair H, Nokes D, Gessner B, Dherani M, Madhi S, Singleton R . Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010; 375(9725):1545-55. PMC: 2864404. DOI: 10.1016/S0140-6736(10)60206-1. View

12.

Ogra P . Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev. 2004; 5 Suppl A:S119-26. PMC: 7172639. DOI: 10.1016/s1526-0542(04)90023-1. View

13.

Alan S, Erdeve O, Cakir U, Akduman H, Zenciroglu A, Akcakus M . Outcome of the Respiratory Syncytial Virus related acute lower respiratory tract infection among hospitalized newborns: a prospective multicenter study. J Matern Fetal Neonatal Med. 2015; 29(13):2186-93. DOI: 10.3109/14767058.2015.1079614. View

14.

Cangiano G, Nenna R, Frassanito A, Evangelisti M, Nicolai A, Scagnolari C . Bronchiolitis: Analysis of 10 consecutive epidemic seasons. Pediatr Pulmonol. 2016; 51(12):1330-1335. PMC: 7167938. DOI: 10.1002/ppul.23476. View

15.

Karron R, Buchholz U, Collins P . Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol. 2013; 372:259-84. PMC: 4794267. DOI: 10.1007/978-3-642-38919-1_13. View

16.

Vitelli A, Nicosia A . Virus . virus: adenovirus vectored vaccine to defeat respiratory syncytial virus. Ann Transl Med. 2017; 4(24):489. PMC: 5233505. DOI: 10.21037/atm.2016.12.08. View

17.

Rossi G, Medici M, Arcangeletti M, Lanari M, Merolla R, di Luzio Paparatti U . Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr. 2007; 166(12):1267-72. PMC: 2042510. DOI: 10.1007/s00431-007-0418-y. View

18.

Kim J, Chang J . In Hot Pursuit of the First Vaccine Against Respiratory Syncytial Virus. Yonsei Med J. 2016; 57(4):809-16. PMC: 4951454. DOI: 10.3349/ymj.2016.57.4.809. View

19.

Jozwik A, Habibi M, Paras A, Zhu J, Guvenel A, Dhariwal J . RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. Nat Commun. 2015; 6:10224. PMC: 4703893. DOI: 10.1038/ncomms10224. View

20.

Bollani L, Baraldi E, Chirico G, Dotta A, Lanari M, Del Vecchio A . Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr. 2015; 41:97. PMC: 4681171. DOI: 10.1186/s13052-015-0203-x. View